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Targeting a host factor essential for the replication of different
viruses but not for the cells offers a higher genetic barrier to the
development of resistance, may simplify therapy regimens for coin-
fections, and facilitates management of emerging viral diseases. DEAD-
box polypeptide 3 (DDX3) is a human host factor required for the
replication of several DNA and RNA viruses, including some of the
most challenging human pathogens currently circulating, such as
HIV-1, Hepatitis C virus, Dengue virus, and West Nile virus. Herein,
we showed for the first time, to our knowledge, that the inhibition
of DDX3 by a small molecule could be successfully exploited for the
development of a broad spectrum antiviral agent. In addition to the
multiple antiviral activities, hit compound 16d retained full activity
against drug-resistant HIV-1 strains in the absence of cellular
toxicity. Pharmacokinetics and toxicity studies in rats confirmed a
good safety profile and bioavailability of 16d. Thus, DDX3 is here
validated as a valuable therapeutic target.
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Most of the current therapeutic approaches to fight viraldiseases target unique components or enzymes of a given
virus with direct-acting antivirals. Although therapeutically highly
successful, direct-acting antivirals are still suffering shortcomings,
such as drug resistance, poor adherence in selected patient groups,
and associated toxicity (1, 2). In addition, virtually no broad
spectrum antivirals are currently available. An alternative ap-
proach currently exploited in antiviral research is the targeting of
host proteins. Examples include Maraviroc (approved for the
treatment of HIV-1 infection) and Alisporivir [in phase III trials
for anti-Hepatitis C virus (HCV) therapy] (3, 4). Viruses as oblig-
atory parasites dependent on the host cell machinery for replica-
tion, protein expression, and assembly of progeny particles (5–7).
RNA viruses, in particular, have high mutation rates owing to their
error-prone polymerases and rapidly generating drug-resistant
variants (8–10). On this basis, blocking host cell factors required by
different viruses for their replication might be a low cost and short
time but effective route to develop broad spectrum antivirals
able to limit the occurrence of drug resistance (11, 12).
Recent studies have revealed that the cellular ATPase/RNA
helicase X-linked DEAD-box polypeptide 3 (DDX3) is an essential
host factor for the replication of viruses belonging to different
families: CMV (13) (Herpesviridae), HIV-1 (14) (Retroviridae),
HCV (15–18), Japanese Encephalitis virus (19), Dengue virus
(DENV) (20), West Nile virus (WNV; Flaviviridae) (21), Vaccinia
virus (22–24) (Poxviridae), and Norovirus (25) (Caliciviridae). The
exact mechanisms of interaction of this protein with individual
pathogens are still poorly understood (26). Nonetheless, DDX3
is being regarded as an interesting target for the development of
novel antiviral compounds (27, 28).
For example, targeting DDX3 might offer the possibility of
simultaneously treating patients for HIV and HCV coinfections.
Several inhibitors of the ATPase activity of DDX3 have been
recently identified (29–34); however, an ATP-mimetic compound
may have a low degree of selectivity in vivo because of the possi-
bility of interacting with many targets (35).
Results and Discussion
In a recent work, we designed and validated the first small mol-
ecule DDX3 inhibitors, to our knowledge, specifically targeting its
RNA binding site (Fig. 1) (36). The most promising molecule was
compound 2, with both antihelicase activity against DDX3 (IC50 =
1 μM) and inhibitory effects on HIV-1 replication in peripheral
blood mononuclear cells [half-maximal effective concentration
(EC50) = 10 μM].
Pursuing this research line, a structure-based optimization pro-
cess was prosecuted herein on compound 2, resulting in the iden-
tification of a new family of more potent DDX3 inhibitors.
Because of the lack of a crystal structure of human DDX3
bound to RNA (closed conformation), we exploited an homology
model previously built by us using the closed conformation of
Significance
Human DEAD-box polypeptide 3 (DDX3) is an ATPase/RNA
helicase involved in the replication of many viral pathogens.
We reported herein the first inhibitor, to our knowledge, of the
helicase binding site of DDX3 endowed with a broad spectrum
antiviral activity [HIV-1 WT, HIV drug-resistant strains, Hepatitis
C virus (HCV), Dengue virus (DENV), and West Nile virus (WNV)].
The good toxicity profile suggests that the DDX3 activity, al-
though essential for viruses, could be dispensable to the cells,
validating DDX3 as a pharmaceutical target. Our results clearly
showed that DDX3 inhibitors could be exploited to treat HIV/
HCV coinfections, emerging infectious diseases (such as DENV
and WNV), and HIV-1 patients carrying drug-resistant strains.
Each of these three medical conditions currently represents a
major challenge for clinical treatment.
Author contributions: G.M. and M.B. designed research; A.B., R.F., C.T., F.B., M.S., J.E., R.B.,
S.F., M.A.M., J.P.M., A.M., F.S., M.Z., and A.G. performed research; C.Z. and E.S. analyzed
data; and A.B. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
Freely available online through the PNAS open access option.
1To whom correspondence may be addressed. Email: maga@igm.cnr.it or botta.maurizio@
gmail.com.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1522987113/-/DCSupplemental.
www.pnas.org/cgi/doi/10.1073/pnas.1522987113 PNAS Early Edition | 1 of 6
M
ED
IC
A
L
SC
IE
N
CE
S
Drosophila Vasa DEAD-box helicase (Protein Data Bank ID
code 2DB3) as a template (Fig. 2) (37).
Similar to the RNA strand (Fig. 2, yellow stick), compound 2
(Fig. 2, green stick) establishes important polar contacts with
Arg276, Arg480, and Pro274. Furthermore, it makes hydrophobic
interactions with Phe357, His472, Lys451, and Val500. However,
our modeling analysis revealed the presence in the binding pocket
of two unexplored areas that could be exploited in search of addi-
tional interactions (Fig. 2, cyan and magenta circles). Thus, a small
library of compound 2 derivatives has been designed and synthe-
sized, introducing modifications to probe these two regions and
expand available structure–activity relationship (SAR) data. Slight
modifications included the replacement of the nitro group with the
isosteric carboxyl group and the substitution of the methyl–phenyl
ring with a cyclohexyl moiety. Furthermore, a naphthyl ring was
inserted in place of the tolyl terminus to make additional interac-
tions with Arg503 and Val500. Next, more pronounced substitutions
have been made by inserting a substituted triazole ring instead of
the nitro group, which allowed the exploration of additional inter-
actions involving residues Arg326 and Gly302. The para position
was predicted by docking studies as the most appropriate for such
Fig. 1. 2D structures of the known human DDX3 inhibitors targeting the
RNA binding pocket.
Fig. 2. Graphical representation of the DDX3 RNA binding site. The RNA
strand is represented as yellow carbon sticks. The binding mode of com-
pound 2 (green carbon sticks) was predicted by docking studies. Hydrogen
bond interactions are visualized as black dashed lines. Compound 2 occupies
a little part of the large pocket, and the two regions circled in magenta and
cyan are unexplored by this ligand.
Table 1. DDX3 antienzymatic activity
n.d., Not determined.
*Compound precipitated during assays.
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kinds of substitutions, and side chains at four positions were se-
lected, taking into account the interactions into the pocket.
Synthesis of compounds 2–9 (Fig. S1) and 16a–16g (Fig. S2) is
reported in Supporting Information.
The anti-DDX3 activity of compounds was assayed, and results
are shown in Table 1. Remarkably, the modifications aimed at
optimizing the van der Waals contacts of the ligands with Arg276
and Arg326 (derivatives 16a–16g) resulted in an increase of the
helicase inhibitory activity, with the best inhibitors 16d and 16g
having IC50 values of 0.3 and 0.98 μM, respectively.
The inactivity of compound 10 suggests that the presence of an
aromatic moiety is fundamental for the helicase inhibitory ac-
tivity, and is probably due to a crucial cation–π interaction with
Arg503. Compounds 9 and 12 unexpectedly precipitated from
medium in enzymatic assays and were, thus, found inactive,
whereas the ester analog 11 was found moderately active.
The predicted binding mode of 16d within the DDX3 RNA
binding pocket is shown in Fig. 3. Some of the ligand contacts are
coincident with the key interactions made by the parent com-
pound 2. Indeed, the urea NH groups were involved in hydrogen
bonds with the backbone carbonyl oxygen of Pro274, whereas the
triazole ring interacted with the guanidine group of Arg276.
Moreover, the tolyl terminus established hydrophobic interac-
tions with residues Arg503 and Pro274, and the phenyl ring made
hydrophobic contacts with the aromatic side chain of Phe357.
Finally, the butyl substituent at the four position of the triazole
ring made profitable interactions with residues Arg326 and Gly302,
was unexploited by compound 2, and was probably responsible for
the improved antihelicase activity.
According to the proposed mode of binding, 16d behaved as a
competitive inhibitor with respect to the RNA substrate, which
can be seen by the decrease in its inhibition potency as a function
of increasing RNA substrate concentrations (Fig. 4).
The most active DDX3 inhibitor 16d was then tested against
HIV, HCV, WNV, and DENV. Results are summarized in Table
2. Remarkably, 16d showed a broad spectrum of antiviral activ-
ity, being able to inhibit the replication of all of these viruses with
EC50 values ranging from 0.97 to 16.5 μM. No toxicity was found
in three different cell culture systems (LucUbiNeo-ET cells and
Hepato cellular carcinoma cells) as a demonstration that the in-
hibition of a cellular cofactor essential for the viruses but not for
the cells can represent a successful strategy for the development of
novel antiviral agents. For comparison purpose, we also tested
hit compound 2 that was previously published (36) against HCV-
infected cells, but despite its activity against DDX3, it was found
inactive (EC50 > 86 μM).
The NS3 protein of both HCV and DENV is an RNA helicase
that belongs to the same family of DDX3. To exclude the in-
volvement of such viral enzymes in the activities of 16d, we tested
this compound against NS3 proteins of HCV and DENV as well
as against another cellular member of the DEAD-box family,
namely DDX1. We also tested the ability of 16d in the inhibition
of the ATPase activity of DDX3. As shown in Table 3, 16d was
found to be completely inactive against the ATPase of DDX3,
DDX1 helicase, and DENV NS3 helicase. It showed moderate
activity against the HCV NS3 helicase, which was, however, 56-
and 17-fold lower than the activity against DDX3 helicase and
HCV proliferation, respectively.
The antiviral activity of compound 16d was also evaluated against
HIV-1 strains carrying clinically relevant mutations conferring high-
level resistance to most classes of antivirals approved to treat HIV
infection (Table 4 and Table S1). Compound 16d retained full
activity against all of the resistant viruses tested, confirming its novel
mechanism of action and the potential to overcome HIV resistance.
A few in vitro experiments were then conducted to quickly
establish the absorption/stability of compound 16d: aqueous
solubility (pH 7.4 buffer), parallel artificial membrane permeability
Table 2. Antiviral activities
Virus Strain Cell type EC50 16d (μM) CC50 16d (μM) EC50 10 (μM) CC50 10 (μM) EC50 16f (μM) CC50 16f (μM)
HIV* NL4-3 PBMCs 1.1 >200 110 >200 >50 50
HCV† Replicon LucUbiNeo-ET 0.97 49.77 >80 80 >36 36
DENV‡ 2, New Guinea C Huh7 2.55 >200 nt nt nt nt
WNV‡ NY99 Huh7 16.5 >200 nt nt nt nt
CC50, half-maximal cytotoxic concentration; EC50, half-maximal effective concentration; nt, Not tested; PBMC, peripheral blood mononuclear cell.
*Evaluated in PBMCs.
†Evaluated in LUNET:LucUbiNeo-ET cells.
‡Evaluated in Huh7:Hepato cellular carcinoma cells.
Fig. 3. Binding mode of compound 16d (purple sticks). For comparison
purpose, compound 2 (green sticks) was also visualized.
Fig. 4. Dose–response curves for DDX3 helicase activity inhibition by 16d at
increasing dsRNA substrate concentrations.
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assay, and human liver microsome stability determination
(Table 5). Despite the fact that the aqueous solubility is just
outside of the range of recommended values for a drug (−6 <
LogS < −1), the excellent metabolic stability and the good
passive membrane permeability make 16d a good lead candi-
date for additional development.
To better evaluate toxicity and biodistribution of compound
16d, we finally performed several preliminary in vivo studies; 16d
was administered to Wistar rats by tail vein in a single systemic
dose (0.05 mL per dose) at high-dose levels of 20 mg/kg. There
were no treatment-related adverse effects on clinical chemistry
analysis of serum for the measurement of biochemical parame-
ters (including liver enzymes, such as alanine aminotransferase,
aspartate aminotransferase, and glutamate dehydrogenase), urea,
creatinine, triglycerides, LDLs, and HDLs. Urine analysis pa-
rameters for treated rats did not show any significant difference
from the respective control groups. Histopathological analysis
Table 3. Enzymatic data on compound 16d
ATPase
DDX3 IC50 (μM)
DDX1
IC50 (μM)
NS3 (DENV)
IC50 (μM)
NS3 (HCV)
IC50 (μM)
>200* >200 >200 16.8
*The value >200 indicates that less than 20% of inhibition was observed at
200 μM, the highest concentration that was tested.
Table 4. Antiviral activity of compound 16d against HIV-1
strains carrying the most common patterns of resistance
mutations selected by drugs currently used to treat
HIV-1 infection
HIV-1 strain*
Drug
resistance
class
IC50 (95%
confidence
interval; μM) Fold change†
114‡ WT 1.11 (0.31–3.90) —
11808 PIs 0.23 (0.08–0.65) 0.2
7406 NRTIs 0.33 (0.13–0.87) 0.3
7404 NRTIs 0.22 (0.11–0.47) 0.2
12227 NNRTIs 0.94 (0.21–1.34) 0.8
12235 NNRTIs 0.36 (0.15–0.87) 0.3
11845 INIs 0.37 (0.26–0.52) 0.3
INI, integrase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhib-
itor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
—, no fold change.
*NIH AIDS Reagent Program catalog number (https://www.aidsreagent.org).
†Resistant strain IC50 to WT strain IC50 ratio.
‡NL4-3 HIV-1 WT reference strain.
Table 5. 16d in vitro absorption, distribution, metabolism, and
excretion (ADME) studies
Papp* Membrane retention† LogS‡ HLM stability§
2.86·10−6 19.1 −7.05 99
HLM, human liver microsome; Papp, apparent permeability.
*Papp reported in centimeters·seconds−1.
†Membrane retention expressed as percentage.
‡Aqueous solubility.
§HLM metabolic stability expressed as percentage of unmodified parent drug.
Fig. 5. Representative images of the histological examination of H&E-stained sections of (A1–E1) livers, (A2–E2) kidneys, and (A3–E3) brains from three
groups of rats. (A1–A3 and B1–B3) VG. (C1–C3 and D1–D3) TG. (E1–E3) WT group. Treated rats do not exhibit abnormal histopathological changes compared
with the control group. The microphotographs were taken using a digital camera (Nikon SLR-D3000) at original magnifications of 100× and 200×. gt,
Glomerular tuft; U, urinary space.
Table 6. Pharmacokinetic parameters of 16d after i.v.
administration at a dose of 10 mg·kg−1
Pharmacokinetic parameters 16d*
Dose (mg/kg) 10.00
MRT (h) 3.98 ± 0.38
AUC0–∞ (μg × h/mL) 39.95 ± 13.50
AUC0–24 (μg × h/mL) 39.77 ± 13.51
CL (mL/min) 1.29 ± 0.54
t1/2β (h) 3.19 ± 0.24
AUC, area under the plasma concentration–time curve; CL, plasma clear-
ance; MRT, mean residence time; t1/2β, plasma half-life.
*All data are expressed as means ± SDs (n = 3).
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of the liver was free from any pathological abnormality, and
H&E-stained sections appeared normal, with regular cellular ar-
chitecture. The hepatic cells had intact cytoplasm, sinusoidal
spaces, prominent nucleus, and nucleolus (Fig. 5). Renal tissue of
all animal groups showed preserved renal parenchyma with nor-
mal appearance of glomerular tuft and urinary space (Fig. 5).
Also, histological analyses of brain tissue samples showed no ob-
vious uncharacteristic changes in all animal groups. In conclusion,
16d was found to possess excellent biocompatibility, and Wistar
rats showed a good tolerance to the dose of 20 mg/kg.
The pharmacokinetic analysis of compound 16d was finally
conducted. The main pharmacokinetic parameters from single-
compartment model analysis are summarized in Table 6. The
half-life elimination and the plasmatic clearance values denoted
that 16d was rapidly eliminated after i.v. administration.
The mean plasma concentration–time curves after i.v. ad-
ministration are illustrated in Fig. 6A. Tissue distribution of 16d
in rat after i.v. administration is presented in Fig. 6B. Higher
concentration of 16d was found in adipose tissue followed by
kidney, testicle, liver, and brain in that order, which can be at-
tributed to the blood flow in this organs.
In conclusion, we report herein the discovery of a novel series
of human helicase DDX3 inhibitors. Among them, compound
16d represents the first compound, to our knowledge, achieving
broad spectrum antiviral activity (HIV, HCV, DENV, and
WNV) in infected cells, targeting a host factor. Compound 16d
was active against HIV-1 drug-resistant strains, suggesting that
DDX3 targeting agents may be able to treat HIV/HCV coin-
fections, patients harboring drug-resistant viruses, and emerg-
ing viral diseases, for which no specific drugs are available.
Moreover, the good toxicity profile suggests that the DDX3
activity, although essential for viral replication, may be dis-
pensable to the cell as shown by preclinical studies. This result
represents a step forward in the fight against infectious diseases
and opens a new scenario in the drug development process.
Materials and Methods
Detailed procedures for the synthesis and characterization of compounds
are provided in Supporting Information.
Absorption, distribution, metabolism, and excretion (ADME) experiments,
assay protocols, and pharmacokinetic and toxicity studies can be found in
Supporting Information.
The rat experiments were performed under a protocol approved by the In-
stitutional Animal Use and Care Committee at the Università Cattolica del Sacro
Cuore (permit no. EE21; March 18, 2014) and authorized by the ItalianMinistry of
Health according to the Legislative Decree 116/92, which implemented the Eu-
ropean Directive 86/609/EEC on laboratory animal protection in Italy. Animal
welfare was routinely checked by veterinarians of the Service for AnimalWelfare.
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